DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02201550

Completed

Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide

Regulation of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide (Victoza)

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

9

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥27•Male

Primary endpoint

•Number of specific immune cells in blood detected by flow cytometry

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02201550
Org study IDH-2-2012-148-KLB

Timeline

Milestones

Study first posted2014-07-28estimated
Last update posted2014-07-28estimated
Study start2013-02 (month precision)
Primary completion2014-04actual (month precision)
Study completion2014-04actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexMale
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Patients with type 2 diabetes undertaking treatment with liraglutide

Inclusion criteria

•Type 2 diabetes
•BMI > 27 kg/m2
•Planed start of treatment with liraglutide
•Age > 18 years

Exclusion criteria

•Infection or active inflammatory disorder
•Immunomodulating treatment (i.e nonsteroidal antiinflammatory drugs, glucocorticoids)
•Smoking
•Alcohol consumption > 14 beverages/week
•Former bariatric surgery

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Change in number of specific immune cells in blood detected by flow cytometry

Time frame:Before and 12 weeks after initiation of liraglutide treatment

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.